Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Treatment of rheumatoid vasculitis

Patrick Whelan, MD, PhD
Section Editor
Gene G Hunder, MD
Deputy Editor
Paul L Romain, MD


The term “rheumatoid vasculitis” (RV) refers specifically to a protean, inflammatory process in patients with rheumatoid arthritis (RA) that is centered on the blood vessel wall itself. Although RV has a range of disease severity, the condition may be associated with substantial potential morbidity, may require intensive immunosuppressive therapy, and may lead to a significantly higher mortality than does RA itself. The disease typically occurs in patients with longstanding, erosive RA. RV may affect a wide range of blood vessel types, from medium-sized muscular arteries to somewhat smaller arterioles or post-capillary venules. Within a given patient, clinical features of both medium- and small-vessel disease may be found. RV may lead to necrosis, blood vessel occlusion, and tissue ischemia in a manner that resembles other forms of systemic vasculitis.

In its tendency to affect medium-sized arteries and involve the skin, peripheral nerves, eyes, heart, muscles, and other organs, RV often has a clinical appearance similar to polyarteritis nodosa. (See "Clinical manifestations and diagnosis of polyarteritis nodosa in adults".)

The treatment of RV is the focus of this topic review. Many of the standard treatment practices for RV have been adapted from those for other forms of systemic vasculitis, particularly granulomatosis with polyangiitis (Wegener’s). The pathogenesis, clinical manifestations, and diagnosis of RV are presented separately. (See "Etiology and pathogenesis of rheumatoid vasculitis" and "Clinical manifestations and diagnosis of rheumatoid vasculitis".)


In considering treatment approaches for the patient with rheumatoid vasculitis (RV), an understanding of the clinical context in which this extraarticular manifestation of rheumatoid arthritis (RA) occurs is essential. The typical patient with RV has suffered from RA for at least a decade before systemic vasculitis becomes apparent. At the time of RV onset, unfortunately, patients who have already incurred considerable morbidity from RA and its therapies require intensive, potentially toxic treatments more than ever.

The incidence of RV appears to be decreasing since the 1980s, suggesting that more aggressive treatment of RA may help to prevent the development of RV [1,2]. (See "Clinical manifestations and diagnosis of rheumatoid vasculitis", section on 'Epidemiology and risk factors'.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Feb 2017. | This topic last updated: Mar 12, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol 2011; 38:983.
  2. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008; 24:469.
  3. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.
  4. Hellmann M, Jung N, Owczarczyk K, et al. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:929.
  5. Assmann G, Pfreundschuh M, Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clin Exp Rheumatol 2010; 28:81.
  6. Bywaters EG. A Variant of Rheumatoid Arthritis resembling Palindromic Rheumatism. Ann Rheum Dis 1949; 8:1.
  7. Watts RA, Carruthers DM, Scott DG. Isolated nail fold vasculitis in rheumatoid arthritis. Ann Rheum Dis 1995; 54:927.
  8. Price-Forbes AN, Watts RA, Lane SE, et al. Do we need to treat isolated nailfold vasculitis (NFV) in rheumatoid arthritis (RA) more aggressively? Abstract 848, American College of Rheumatology annual scientific meeting, October 2002.
  9. Oien RF, Håkansson A, Hansen BU. Leg ulcers in patients with rheumatoid arthritis--a prospective study of aetiology, wound healing and pain reduction after pinch grafting. Rheumatology (Oxford) 2001; 40:816.
  10. Tuveri M, Generini S, Matucci-Cerinic M, Aloe L. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet 2000; 356:1739.
  11. Kamali S, Polat NG, Kasapoglu E, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis. Clin Rheumatol 2005; 24:673.
  12. Harper L, Cockwell P, Howie AJ, et al. Focal segmental necrotizing glomerulonephritis in rheumatoid arthritis. QJM 1997; 90:125.
  13. Kawakami T, Yamazaki M, Kawasaki K, et al. Therapeutic effect of argatroban on rheumatoid vasculitis with antiphosphatidylserine-prothrombin complex antibody. Arch Dermatol 2008; 144:1075.
  14. Gravallese EM, Corson JM, Coblyn JS, et al. Rheumatoid aortitis: a rarely recognized but clinically significant entity. Medicine (Baltimore) 1989; 68:95.
  15. Slobodin G, Naschitz JE, Zuckerman E, et al. Aortic involvement in rheumatic diseases. Clin Exp Rheumatol 2006; 24:S41.
  16. Kaneko S, Yamashita H, Sugimori Y, et al. Rheumatoid arthritis-associated aortitis: a case report and literature review. Springerplus 2014; 3:509.
  17. García-Martínez A, Prieto-González S, Giménez PA, et al. Aortitis and aortic aneurysm in systemic vasculitis. In: Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture, Grundmann R. (Ed), InTech, 2011.
  18. Rojo-Leyva F, Ratliff NB, Cosgrove DM 3rd, Hoffman GS. Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases. Arthritis Rheum 2000; 43:901.
  19. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984; 76:377.
  20. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91:1253.
  21. Messmer EM, Foster CS. Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea 1995; 14:408.
  22. Breedveld FC. Vasculitis associated with connective tissue disease. Baillieres Clin Rheumatol 1997; 11:315.
  23. Abel T, Andrews BS, Cunningham PH, et al. Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes. Ann Intern Med 1980; 93:407.
  24. Puéchal X, Gottenberg JE, Berthelot JM, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry. Arthritis Care Res (Hoboken) 2012; 64:331.
  25. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180.
  26. Flossmann O, Jones RB, Jayne DR, Luqmani RA. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis 2006; 65:841.
  27. Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991; 151:2249.
  28. Combe B, Didry C, Gutierrez M, et al. Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis. Eur J Med 1993; 2:153.
  29. Nicholls A, Snaith ML, Maini RN, Scott JT. Proceedings: Controlled trial of azathioprine in rheumatoid vasculitis. Ann Rheum Dis 1973; 32:589.
  30. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.
  31. Hoffman GS, Cinta-Cid M, Rendt KE, et al. Prednisone and Infliximab for Giant Cell Arteritis: A Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety. Ann Intern Med 2006.
  32. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41:1126.
  33. Unger L, Kayser M, Nüsslein HG. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 2003; 62:587.
  34. Garcia-Porrua C, González-Gay MA. Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor alpha monoclonal antibody infliximab. Rheumatology (Oxford) 2002; 41:234.
  35. van der Bijl AE, Allaart CF, Van Vugt J, et al. Rheumatoid vasculitis treated with infliximab. J Rheumatol 2005; 32:1607.
  36. Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? J Rheumatol 2006; 33:433; author reply 433.
  37. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002; 47:445.
  38. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000; 27:2041.
  39. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999; 131:634.
  40. Livermore PA, Murray KJ. Anti-tumour necrosis factor therapy associated with cutaneous vasculitis. Rheumatology (Oxford) 2002; 41:1450.
  41. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002; 41:116.
  42. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004; 31:1955.
  43. Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: longterm followup with special reference to amyloidosis. J Rheumatol 1999; 26:898.
  44. Puéchal X, Said G, Hilliquin P, et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995; 38:1618.
  45. Karlson EW, Lee IM, Cook NR, et al. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum 1999; 42:910.
  46. Struthers GR, Scott DL, Delamere JP, et al. Smoking and rheumatoid vasculitis. Rheumatol Int 1981; 1:145.
  47. Albano SA, Santana-Sahagun E, Weisman MH. Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 2001; 31:146.
  48. Voskuyl AE, Zwinderman AH, Westedt ML, et al. The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum 1996; 39:266.
  49. Makol A, Crowson CS, Wetter DA, et al. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology (Oxford) 2014; 53:890.
  50. Ntatsaki E, Mooney J, Scott DG, Watts RA. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology (Oxford) 2014; 53:145.
  51. Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) 1981; 60:288.